Physician profile
Bashab Banerji
NPI 1659379717
$25,898.67
in general payments reported to CMS, 2019-2025
49 companies · $4,633 in 2025
The $4,633 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,925 · 2020: $659 · 2021: $2,661 · 2022: $5,102 · 2023: $4,756 · 2024: $3,161 · 2025: $4,633.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,009 · Honoraria: $3,000 · Consulting Fee: $500 · Education: $41.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,008.95 |
| Honoraria | $3,000.00 |
| Consulting Fee | $500.00 |
| Education | $41.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $11,813.41 | 2019-2025 | Zoryve, Seglentis, Livalo |
| Astrazeneca Pharmaceuticals Lp | $2,702.27 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Biohaven Pharmaceuticals, INC. | $1,220.33 | 2021 | |
| Amgen INC. | $1,186.80 | 2019-2025 | Repatha, Prolia, Evenity |
| Bayer Healthcare Pharmaceuticals INC. | $789.17 | 2022-2025 | |
| Glaxosmithkline, LLC. | $777.42 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novartis Pharmaceuticals Corporation | $613.30 | 2019-2025 | |
| Novo Nordisk INC | $603.16 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Radius Health, INC. | $600.65 | 2020-2025 | Tymlos |
| Abbott Laboratories | $559.39 | 2021-2025 | Freestyle Libre 3, Proclaim |
| Abbvie INC. | $541.24 | 2019-2025 | Vraylar, Synthroid |
| Dexcom, INC. | $393.16 | 2021-2025 | Dexcom G6 Transmitter |
| Amarin Pharma, INC. | $384.50 | 2019-2021 | |
| Esperion Therapeutics, INC. | $293.13 | 2020-2025 | Nexletol, Nexlizet |
| Idorsia Pharmaceuticals US INC | $234.54 | 2022-2023 | Quviviq |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bashab Banerji listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.